국내 노인 대상포진 환자에서 분리된 수두대상포진 바이러스의 유전형
Genotype of Varicella Zoster Virus Isolated from Korean Elderly Patients with Herpes Zoster
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Herpes zoster develops via reactivation of the latent varicella zoster virus (VZV) in neuronal ganglia as host immunity declines. In Korea, seroprevalence of VZV is very high and population at risk for herpes zoster is increasing. The goal of this study is to evaluate the infection rate of the VZV and the lifetime prevalence of herpes zoster, and to determine the genotype of VZV. Material and Method: Serum IgG antibody titer was measured in 399 patients. Lifetime prevalence of herpes zoster was evaluated through a survey of 2,054participants. VZV was isolated by cell culture technique using MRC-5 cells. To determine the genotype of VZV, ORF 22, 38, 54, 62 were amplified by PCR, and after digestion of the PCR products with enzymes pst I, bgl I, and sma I, restrictionfragment-length-polymorphism (RFLP) was analysed. The amplified ORF 22 PCR product was sequenced and checked for single nucleotide polymorphisms. Results: The overall seroprevalence of VZV IgG in adults was 93.9% (375/399). The overall lifetime prevalence of herpes zoster was 13.7% (282/2,054). Of the patients with herpes zoster, 17.7% (50/282) of patients experienced postherpetic neuralgia for more than one month. All 22 VZV isolates were of J genotype; 21 (95.4%) isolates were all pst I+ bgl I+ smaI¯, and 1 (4.5%) isolate was pst I¯ bgl I+ smaI¯ (pOka) genotype. Conclusions: The seroprevalece of VZV IgG antibody was 93.9% in adults. The lifetime prevalence of herpes zoster was 13.7%. The genotype of VZV isolated from adults over 60 years old were all of J genotype.
Abstract
Background: Herpes zoster develops via reactivation of the latent varicella zoster virus (VZV) in neuronal ganglia as host immunity declines. In Korea, seroprevalence of VZV is very high and population at risk for herpes zoster is increasing. The goal of this study is to evaluate the infection rate of the VZV and the lifetime prevalence of herpes zoster, and to determine the genotype of VZV. Material and Method: Serum IgG antibody titer was measured in 399 patients. Lifetime prevalence of herpes zoster was evaluated through a survey of 2,054participants. VZV was isolated by cell culture technique using MRC-5 cells. To determine the genotype of VZV, ORF 22, 38, 54, 62 were amplified by PCR, and after digestion of the PCR products with enzymes pst I, bgl I, and sma I, restrictionfragment-length-polymorphism (RFLP) was analysed. The amplified ORF 22 PCR product was sequenced and checked for single nucleotide polymorphisms. Results: The overall seroprevalence of VZV IgG in adults was 93.9% (375/399). The overall lifetime prevalence of herpes zoster was 13.7% (282/2,054). Of the patients with herpes zoster, 17.7% (50/282) of patients experienced postherpetic neuralgia for more than one month. All 22 VZV isolates were of J genotype; 21 (95.4%) isolates were all pst I+ bgl I+ smaI¯, and 1 (4.5%) isolate was pst I¯ bgl I+ smaI¯ (pOka) genotype. Conclusions: The seroprevalece of VZV IgG antibody was 93.9% in adults. The lifetime prevalence of herpes zoster was 13.7%. The genotype of VZV isolated from adults over 60 years old were all of J genotype.
참고문헌 (44)
- Schmader K, "Herpes zoster in older adults", Clin Infect Dis, 32, pp.1481~1486 (2001)
- Brisson M, "Epidemiology of varicella zoster virus infection in Canada and the United Kingdom", Epidemiol Infect, 27, pp.305~314 (2001)
- Hope-Simpson RE, "The nature of herpes zoster: a long-term study and a new hypothesis", Proc R Soc Med, 58, pp.9~20 (1965)
- Donahue JG, "The incidence of herpes zoster", Arch Intern Med, 155, pp.1605~1609 (1995)
- Gilden DH, "Neurologic complications of the reactivation of varicella-zoster virus", N Engl J Med, 342, pp.635~645 (2000)
- Gnann JW Jr, "Clinical practice. Herpes zoster", N Engl J Med, 347, pp.340~346 (2002)
- Thomas SL, "What does epidemiology tell us about risk factors for herpes zoster?", Lancet Infect Dis, 4, pp.26~33 (2004)
- Hope-Simpson RE, "Postherpetic neuralgia", J R Coll Gen Pract, 25, pp.571~575 (1975)
- Kost RG, "Postherpetic neuralgia--pathogenesis, treatment, and prevention", N Engl J Med, 335, pp.32~42 (1996)
- "Population census 2005. Age over 60 years, City and province statistics"[URL]
- 박석열, "최근 10년간 대상포진으로 내원한 환자들의 임상적 관찰", 대한피부과학회지, 42(12), pp.1531~1535 (2004), 대한피부과학회
- 강철인, "젊고 건강한 한국 군인들에서 대상포진의 발생률", Infection and Chemotherapy, 38(1), pp.45~46 (2006), 대한감염학회
- Kim SY, "A 5 - Year Clinical Study on Herpes Zoster: 1990 - 1994", Korean J Dermatol, 35, pp.266~272 (1997)
- Shin DY, "Statistical analysis of herpes zoster in chuncheon and the northern kangwon province ( 1994-1996 )", Korean J Dermatol, 36, pp.422~429 (1998)
- Jumaan AO, "Incidence of herpes zoster, before and after varicellavaccination-associated decreases in the incidence of varicella, 1992-2002", J Infect Dis, 191, pp.2002~2007 (2005)
- Adams SG, "Restriction fragment differences between the genomes of the Oka varicella vaccine virus and American wild-type varicella-zoster virus", J Med Virol, 29, pp.38~45 (1989)
- Yih WK, "The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003", BMC Public Health, 5, pp.68~ (2005)
- LaRussa P, "Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wildtype varicella-zoster virus isolates", J Virol, 66, pp.1016~1020 (1992)
- Loparev VN, "Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping", J Virol, 78, pp.8349~8358 (2004)
- Kilgore PE, "Varicella in Americans from NHANES III: implications for control through routine immunization", J Med Virol, 70(Suppl 1), pp.S111~S118 (2003)
- Dayan GH, "Varicella seroprevalence and molecular epidemiology of varicellazoster virus in Argentina, 2002", J Clin Microbiol, 42, pp.5698~5704 (2004)
- 최희정, "일개 대학병원 의료인의 홍역, 풍진, 수두에 대한 감수성", Infection and Chemotherapy, 35(6), pp.401~406 (2003), 대한감염학회
- Kim OJ, "Consistency of the low seroprevalence of human herpesvirus 8 and the rarity of kaposi`s sarcoma in south Korea", Journal of Bacteriology and Virology, 31, pp.275~279 (2001)
- Shin HS, "Prevalence of measles, rubella and varicellazoster antibodies in hospital personnel", Korean J Infect Dis, 29, pp.29~32 (1997)
- Arvin A, "Aging, immunity, and the varicella-zoster virus", N Engl J Med, 352, pp.2266~2267 (2005)
- Arvin AM, "Humoral and cellular immunity to varicella-zoster virus: an overview", J Infect Dis, 197(Suppl 2), pp.S58~S60 (2008)
- Schmader K, "The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine", J Infect Dis, 197(Suppl 2), pp.S207~S215 (2008)
- Yawn BP, "A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction", Mayo Clin Proc, 82, pp.1341~1349 (2007)
- Dworkin RH, "Treatment and prevention of postherpetic neuralgia", Clin Infect Dis, 36, pp.877~882 (2003)
- Davison AJ, "The complete DNA sequence of varicellazoster virus", J Gen Virol, 67, pp.1759~1816 (1986)
- Sauerbrei A, "Different genotype pattern of varicellazoster virus obtained from patients with varicella and zoster in Germany", J Med Virol, 79, pp.1025~1031 (2007)
- Muir WB, "Phylogenetic analysis of varicella-zoster virus: evidence of intercontinental spread of genotypes and recombination", J Virol, 76, pp.1971~1979 (2002)
- Sengupta N, "Varicella-zoster-virus genotypes in East London: a prospective study in patients with herpes zoster", J Infect Dis, 196, pp.1014~1020 (2007)
- Loparev VN, "Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand", J Virol, 81, pp.12758~12765 (2007)
- Loparev V, "Toward universal varicella-zoster virus (VZV) genotyping: diversity of VZV strains from France and Spain", J Clin Microbiol, 45, pp.559~563 (2007)
- Sauerbrei A, "Genotypes of varicella-zoster virus wild-type strains in Germany", J Med Virol, 80, pp.1123~1130 (2008)
- Takayama M, "Application of long PCR method of identification of variations in nucleotide sequences among varicella-zoster virus isolates", J Clin Microbiol, 34, pp.2869~2874 (1996)
- Argaw T, "Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates", J Infect Dis, 181, pp.1153~1157 (2000)
- Gomi Y, "Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus", J Virol, 76, pp.11447~11459 (2002)
- Loparev VN, "Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR", J Clin Microbiol, 38, pp.3156~3160 (2000)
- Quinlivan M, "The molecular epidemiology of varicella-zoster virus: evidence for geographic segregation", J Infect Dis, 186, pp.888~894 (2002)
- Barrett-Muir W, "Genetic variation of varicella-zoster virus: evidence for geographical separation of strains", J Med Virol, 70(Suppl 1), pp.S42~S47 (2003)
- Faga B, "Identification and mapping of single nucleotide polymorphisms in the varicellazoster virus genome", Virology, 280, pp.1~6 (2001)
- Park HK, "Antigen analysis and restriction fragment length polymorphysm of the polymerase chain reaction products of Varicella-Zoster virus wild strains isolated in Korea", J Korean Soc Microbiol, 32, pp.265~274 (1997)